Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P563 Shared decision-making in pregnancy in inflammatory bowel disease: Design of a pregnancy in IBD decision aid (PIDA)

ECCO'20 Vienna

Year: 2020
Authors:

A.J. Williams1, Y. Leung2, K. O’Connor3, V. Huang3

1Department of Gastroenterology, University of New South Wales, Liverpool, Australia, 2Department of Gastroenterology, University of British Columbia, Vancouver, Canada, 3Department of Gastroenterology, University of Toronto, Toronto, Canada

P564 Psychological acceptance of surgery in patients with inflammatory bowel disease undergoing intestinal resection

ECCO'20 Vienna

Year: 2020
Authors:

Y. Hirano1,2, M. Itabashi3, T. Saito4, K. Uchida5, M. Inoue5, A. Katsuhiro2, H. Atsuhiro1, K. Araki1, Y. Nishikawa1, M. Tatsuno1, K. Hideaki1, K. Reiko1

1Inflammatory Bowel Disease Centre, Yokohama City University Medical Centre, Yokohama, Japan, 2Division of Gastroenterology, National Centre for Child Health and Development, Tokyo, Japan, 3Department of Surgery Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan, 4Department of Pediatric Surgery, Chiba University Graduate School of Medicine,Chiba, Japan, 5Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Mie, Japan

P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension

ECCO'20 Vienna

Year: 2020
Authors:

B.E. Sands1, M.T. Abreu2, R.W.L. Leong3, C. Marano4, C.D. O’Brien4, H. Zhang5, Y. Zhou5, J. Johanns5, D. Rowbotham6, T. Hisamatsu7, R.P. Arasaradnam8, E. Scherl9, S. Danese10, L. Peyrin-Biroulet11, UNIFI Investigators

1Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA, 2Department of Gastroenterology, University of Miami Miller School of Medicine, Miami, USA, 3Department of Gastroenterology, The University of New South Wales and Macquarie University, Sydney, Australia, 4Department of Immunology, Janssen Research and Development- LLC, Spring House, USA, 5Department of Clinical Biostats, Janssen Research and Development LLC, Spring House, USA, 6Department of Gastroenterology and Hepatology, Auckland City Hospital, Auckland, New Zealand, 7Department of Internal Medicine, Kyorin University, Tokyo, Japan, 8Department of Gastroenterology, University Hospital Coventry, Warwickshire, UK, 9Jill Roberts Center for Inflammatory Bowel Disease, Weill Cornell Medicine, New York, USA, 10Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy, 11Department of Gastroenterology, Nancy University Hospital, Nancy, France

P566 Assessing the efficacy of biologics in ulcerative colitis: A real-life, observational retrospective multicenter study using the propensity score analysis: The ‘A.U.R.O.R.A.’ comparison study

ECCO'20 Vienna

Year: 2020
Authors:

A. Cassinotti1, N. Mezzina1, D. Di Paolo2, M.V. Lenti3, C. Bezzio4, D. Stradella5, M. Mauri6, V. Zadro1, C. Cortellezzi7, C. Ricci8, V. Casini9, E. Radice10, A. Massari1, S. Ardizzone1, L. Pastorelli2, A. Di Sabatino3, G. Manes4, F. Caprioli11, M. Vecchi11, R. Tari5, P. Occhipinti5, M. Fichera6, P. Invernizzi6, M. Parravicini7, S. Segato7, F. Pace9, P.A. Testoni10, C. Tinelli12, A. De Silvestri12

1Department of Gastroenterology, Luigi Sacco University Hospital, Milan, Italy, 2Gastroenterology and Digestive Endoscopy Unit, IRCCS Policlinico San Donato, San Donato Milanese, Milano, Italy, 3Istituto di Ricovero e Cura a Carattere Scientifico San Matteo Hospital Foundation, University of Pavia, First Department of Medicine, Pavia, Italy, 4ASST Rhodense, Rho and Garbagnate Milanese Hospital, Department of Gastroenterology, Milan, Italy, 5Department of Gastroenterology, ‘Maggiore Della Carità’ Hospital- Novara, Novara, Italy, 6Gastroenterology Division, San Gerardo Hospital- ASST Monza, Monza, Italy, 7Division of Gastroenterology, ASST Sette Laghi, Ospedale di Circolo Fondazione Macchi, Varese, Italy, 8Spedali Civili and University of Brescia, Gastroenterology Section, 1st Medical Clinic, Brescia, Italy, 9Department of Gastroenterology, ASST Bergamo EST-Ospedale Bolognini, Bergamo, Italy, 10Gastroenterology Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy, 11Department of Gastroenterology and Endoscopy, IRCCS Ca’ Granda Foundation, University of Milan, Milano, Italy, 12Fondazione IRCCS Policlinico san Matteo, Servizio di Epidemiologia Clinica e Biometria Direzione Scientifica, Pavia, Italy

P567 Impact of oral ferric maltol and IV iron on health-related quality of life in patients with iron deficiency anaemia and inflammatory bowel disease, and relationship with haemoglobin and serum ironECCO'20 Vienna
Year: 2020
Authors: S. Howaldt1, I. Jacob2, M. Sampson3, F. Akriche4

1MZV für Immunologie, Gastroenterology, Hamburg, Germany, 2Health Economics and Outcomes Research Ltd., Health economics, Cardiff, UK, 3Shield Therapeutics PLC, Medical, London, UK, 4Norgine Ltd., Medical, Rueil Malmaison, France

Corrigendum:

In the originally published version of this poster presentation, the below corrections have been made.

Upon the original publication, the Results section should read: “250 patients were randomised: 125 to FM and 125 to IV FCM. The primary endpoint was not met. Hb, serum iron and HRQoL all improved following both treatments at Week 12. Improvements in SF-36 physical component summary (PCS) and mental component summary (MCS) scores were slightly greater with FM (difference not statistically significant; Table 1). HRQoL improved across all SF-36 domain scores with both FM and FCM, with no statistically significant differences between treatments (Figure 1). HRQoL (MCS and PCS) improvements were positively associated with increases in Hb and serum iron (Table 1).”.

Upon the original publication, the Conclusion should read: “FM provides HRQoL benefits at least as great as those with IV FCM, and may, therefore, provide an oral alternative to IV iron in patients with IBD.” instead of “FM provides non-inferior efficacy to IV FCM with at least as great a benefit to HRQoL and may, therefore, provide an oral alternative to IV iron in patients with IBD.”.

P568 An open-label, multicenter, phase ib, pharmacokinetic (pk) and safety study of a fimh blocker, Sibofimloc (TAK-018/EB8018), in patients with Crohn’s disease (CD)

ECCO'20 Vienna

Year: 2020
Authors:

W. Reinisch1, X. Hébuterne2, A. Buisson3, S. Schreiber4, P. Desreumaux5, J.M. Paillarse6, C. Bonny7

1Medical University of Vienna, Gastroenterology and Hepatology, Vienna, Austria, 2CHU Nice and University Côte d’Azur, Gastroenterology, Nice, France, 3CHU, Gastroenterology, Clermont-Ferrand, France, 4University-Hospital Schleswig-Holstein, Internal medicine, Kiel, Germany, 5CHU Lille, Gastroenterology, Lille, France, 6Enterome Bioscience, Medical Department, Paris, France, 7Enterome Bioscience, Scientific Direction, Paris, France

P569 The role of multidrug-resistant infections in IBD patients undergoing surgery

ECCO'20 Vienna

Year: 2020
Authors:

F. Colombo1, G.M.B. Lamperti1, S. Antinori2, M. Corbellino2, G. Maconi3, S. Ardizzone3, D. Foschi1, G. Sampietro1

1L.Sacco University Hospital, General Surgery, Milan, Italy, 2L.Sacco University Hospital, Infectious Diseases Department, Milan, Italy, 3L.Sacco University Hospital, Gastroenterology Unit, Milan, Italy

P570 The burden of anaemia remains significant over time in patients with inflammatory bowel disease at a tertiary referral centre

ECCO'20 Vienna

Year: 2020
Authors:

K. Singh Singh1, A. Al-Khoury1, Z. Kurti2, L. Gonczi3, P. Golovics3, R. Kohen1, W. Afif1, G. Wild1, E. Seidman1, A. Bitton1, T. Bessissow1, P. Lakatos2

1McGill University, Division of Gastroenterology Department of Medicine, Montreal, Canada, 2Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 3HDF Medical Centre, Division of Gastroenterology, Budapest, Hungary

P571 Self-Medication with steroids in ulcerative colitis: Results of a patient survey

ECCO'20 Vienna

Year: 2020
Authors:

F. Mesonero Gismero1, I. Rodriguez-Lago2, M. Cañas3, S. Claudia4, R. Saldaña4, L. Feo-Lucas5, S. Fernandez5, L. Cea-Calvo5, B. Juliá5

1Hospital Ramón y Cajal, Gastroenterology Department- IBD Unit, Madrid, Spain, 2Hospital de Galdakao, Gastroenterology Department- IBD Unit, Galdakao, Spain, 3Hospital Clinico San Carlos, Gastroenterology Department, Madrid, Spain, 4Spanish confederation of associations of patients with Crohn′s disease and Ulcerative colitis ACCU, Accu, Madrid, Spain, 5Merck Sharp and Dohme of Spain, Medical Affairs Department, Madrid, Spain

P572 Clinical outcomes after discontinuation of anti-tumour necrosis factor-α agents in inflammatory bowel disease patients with clinical remission: KASID multicenter study

ECCO'20 Vienna

Year: 2020
Authors:

J.H. Song1, S.M. Kong1, J. Shin1, G. Seong1, E.A. Kang2, S.K. Park3, S.N. Hong1, Y.S. Kim4, K.B. Bang5, K.O. Kim6, H.S. Lee7, S.B. Kang8, S.Y. Shin9, E.M. Song10, C.H. Choi9, T.J. Kim1, E.R. Kim1, D.K. Chang1, Y.H. Kim1

1Samsung Medical Center, Medicine, Seoul, Korea Republic of, 2Seoul National University College of Medicine, Internal Medicine and Liver Research Institute, Seoul, Korea Republic of, 3Kangbuk Samsung Hospital, Medicine, Seoul, Korea Republic of, 4Seoul Paik Hospital, Internal Medicine, Seoul, Korea Republic of, 5Dankook University College of Medicine, Internal Medicine, Cheonan, Korea Republic of, 6Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea Republic of, 7Inje University Busan Paik Hospital, Internal Medicine, Busan, Korea Republic of, 8Daejeon St. Mary’s Hospital, Internal Medicine, Daejeon, Korea Republic of, 9Chung-Ang University, Internal Medicine, Seoul, Korea Republic of, 10Ewha Womans University Seoul Hospital, Internal Medicine, Seoul, Korea Republic of

P573 Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: an on-going systematic review with meta-analysis

ECCO'20 Vienna

Year: 2020
Authors:

L. Guberna Blanco, O.P. Nyssen, M. Chaparro, J.P. Gisbert

Hospital Universitario de la Princesa, Gastroenterology and Hepatology, Madrid, Spain

P574 Incidence and indicators of suboptimal response to tumour necrosis factor antagonist therapy in Chinese patients with inflammatory bowel disease: Results from the EXPLORE study

ECCO'20 Vienna

Year: 2020
Authors:

J. Li1, Z. Li2, P. Hu3, Z. Wen4, Q. Cao5, X. Zou6, Y. Chen7, Y. Wang8, J. Zhong9, X. Shen10, D. Demuth11, O. Fedeeva11, L. Xie12, J. Chen12, J. Qian1

1Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, 2Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China, 3The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 4West China Hospital, Sichuan University, Chengdu, China, 5Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, 6Nanjing Drum Tower Hospital, Nanjing University School of Medical, Nanjing, China, 7The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 8The First Affiliated Hospital, Dalian Medical University, Dalian, China, 9Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 10Zhongshan Hospital, Fudan University, Shanghai, China, 11Medical Affairs, Takeda Pharmaceutical International AG, Singapore, Singapore, 12Medical Affairs, Takeda China International Trading Company, Beijing, China

P575 Real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn’s disease: The Scottish ustekinumab cohort

ECCO'20 Vienna

Year: 2020
Authors:

N. PLEVRIS1, A. Robertson2, J. Fulforth1, R. Hall3, I. Campbell4, C. Kane5, J. Veryan6, W. Lam6, J. Saunders2, P. Jenkinson1, C. Chuah7, C. Kelly8, D. Watts8, D. Gaya6, J. Macdonald9, H. Jafferbhoy7, J.P. Seenan9, C. Mowat3, D. Sutherland2, G. Naismith10, G. Bain5, I. Arnott1, G. Jones1, C. Lees1

1Department of Gastroenterology, Western General Hospital, The Edinburgh IBD Unit, Edinburgh, UK, 2Department of Gastroenterology, University Hospital Hairmyres, Glasgow, UK, 3Department of Gastroenterology, Ninewells Hospital, Dundee, UK, 4Department of Gastroenterology, Royal Alexandra Hospital, Glasgow, UK, 5Department of Gastroenterology, Aberdeen Royal Infirmary, Aberdeen, UK, 6Department of Gastroenterology, Glasgow Royal Infirmary,Glasgow, UK, 7Department of Gastroenterology, Victoria Hospital, Kirkcaldy, UK, 8Department of Gastroenterology, Forth Valley Royal Hospital, Larbert, UK, 9Department of Gastroenterology, Queen Elizabeth University Hospital, Glasgow, UK, 10Department of Gastroenterology, Royal Alexandra Hospital, Paisley, UK